Search the Newsreel

IMDX Looks 284.7% Overvalued on GF Value™

Insight Molecular Diagnostics Inc (IMDX) is considered 284.7% overvalued based on its GF Value™ despite optimism around future FDA authorization for its GraftAssureDx test and expanded Medicare reimbursement. The company reported a Q2 adjusted EBITDA loss and an upward revision of its cash burn …

Insight Molecular Diagnostics signals ~$8M quarterly cash burn in H2 2026 while targeting FDA authorization later this year

Earnings Call Insights: Insight Molecular Diagnostics (IMDX) Q2 2026 MANAGEMENT VIEW * "It feels great to be coming to you today with line of sight on expected FDA marketing authorization for GraftAssureDx" (President, CEO & Director Joshua Riggs), adding, "We continue to target receipt …

Earnings call transcript: Insight Molecular Diagnostics posts mixed Q2 2026 results

* Insight Molecular Diagnostics Inc. (IMDX [https://seekingalpha.com/symbol/IMDX]) is scheduled to announce Q2 earnings results on Monday, August 10th, after market close. * The consensus EPS estimate is -$0.25, [https://seekingalpha.com/symbol/IMDX/earnings/estimates] and the consensus revenue estimate is $0.44M * Over the last year, IMDX has beaten …

Insight Molecular Diagnostics earnings beat, revenue fell short of estimates

Insight Molecular Diagnostics (NASDAQ: IMDX) reported second-quarter EPS of $-0.230, exceeding analyst estimates of $-0.240. However, the company's revenue of $240K fell short of the consensus estimate of $470.85K. Despite the revenue miss, the company's stock price has shown significant volatility, being down -25.700% …

Insight Molecular Diagnostics: Q2 Earnings Snapshot

The provided content is not an article but rather a privacy notice or a placeholder. It does not contain any information about Insight Molecular Diagnostics or its Q2 earnings. Therefore, no meaningful summary can be generated.

Form 8K Insight Molecular Diagnostics Inc For: 10 August By Investing.com

This article announces the filing of a Form 8K by Insight Molecular Diagnostics Inc. on August 10. The filing is a standard regulatory announcement, and the article provides no further details beyond the company name and filing date. It appears to be a placeholder …

Insight Molecular Diagnostics (Nasdaq: IMDX) reports steep revenue drop but bolsters cash

Insight Molecular Diagnostics (IMDX) reported a steep revenue drop in Q2 2026, with net revenue down sharply to $239,000 from $518,000 in the prior year, and a net loss of $11.3 million. Despite the revenue decline and increased operating expenses, the company bolstered its …

IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx

Insight Molecular Diagnostics Inc. (IMDX) reported its Q2 2026 results and provided an update on the FDA review of its GraftAssureDx product. The company is progressing with the FDA, expecting marketing authorization soon, and highlighted favorable Medicare reimbursement policy changes. IMDX also shared clinical …

AdvanSix Nylon Sales Surge 26% in Q2 2026

AdvanSix reported a 26% surge in nylon sales and an 18% increase in chemical intermediates sales in Q2 2026, despite a subdued industrial demand environment. Total company sales rose 3% year-over-year, driven by favorable pricing, though net income and EPS significantly declined. The company …

Truist Financial Cuts AdvanSix (NYSE:ASIX) Price Target to $18.00

Truist Financial has lowered its price target for AdvanSix (NYSE:ASIX) to $18.00 from $20.00, while maintaining a "hold" rating, suggesting a potential upside of 10.4% from the previous close. This adjustment comes after AdvanSix missed its quarterly earnings and revenue expectations. The consensus among …

Truist cuts AdvanSix stock price target on plant nutrients pressure

Kaplan Fox Investigates The Ensign Group Over Alleged Securities Violations After Stock Drop

Kaplan Fox & Kilsheimer LLP has launched an investigation into The Ensign Group, Inc. (NASDAQ: ENSG) following a report by Hunterbrook Media alleging inadequate patient care and data misrepresentation. The Hunterbrook Media report, titled "Ensign: The Nursing Home Empire Built On Fatal Neglect," caused …

Insight Enterprises (NASDAQ:NSIT) Reaches New 1-Year High After Analyst Upgrade

Insight Enterprises (NASDAQ:NSIT) reached a new 52-week high after JPMorgan Chase & Co. raised its price target from $135 to $160, maintaining a neutral rating. The company reported strong quarterly earnings of $3.86 EPS on $2.40 billion in revenue, exceeding analyst estimates. Despite the …

Ensign Energy Services Inc. (TSX:ESI) Stock Falls as Oilfield Weakness and Investor Caution Pressure Outlook

NSIT Q2 Deep Dive: AI Infrastructure and Operational Focus Drive Outperformance

NSIT Q2 Deep Dive: AI Infrastructure and Operational Focus Drive Outperformance IT solutions integrator Insight Enterprises (NASDAQ:NSIT) reported revenue ahead of Wall Street's expectations in Q2 CY2026, with sales up 14.7% year on year to $2.40 billion. Its non-GAAP profit of $3.86 per share …

IMDX Stock Price and Chart — NASDAQ:IMDX

This article provides an overview of Insight Molecular Diagnostics Inc. (IMDX) stock, including its current price, market capitalization, key financial stats, and performance over various periods. It also highlights analyst opinions, future earnings expectations, and company details, noting the FDA review for GraftAssureDx and …

Insight Enterprises (NSIT) Stock Looks Cheap On Cash Flow And Earnings

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Insight Enterprises stock has had a strong run so far this year, yet the current share price sits below where a Discounted Cash …

Insight Molecular Diagnostics earnings beat, revenue fell short of estimates By Investing.com

Insight Molecular Diagnostics (NASDAQ: IMDX) reported second-quarter EPS of $-0.230, exceeding analyst estimates of $-0.240. However, the company's revenue of $240K fell short of the consensus estimate of $470.85K. Despite the revenue miss, the company's stock price has shown significant volatility, being down -25.700% …

Why Insight Enterprises (NSIT) Is Up 15.8% After AI-Driven Q2 Beat And Raised 2026 Guidance

Insight Enterprises reported past second-quarter 2026 results showing revenue of US$2,399.5 million and net income of US$77.57 million, with basic EPS from continuing operations rising to US$2.58 from US$1.48 a year earlier. The company's earnings were supported by strong demand for AI-ready infrastructure and …

Insight Enterprises (NSIT) Stock May Be 14% Undervalued On Cash Flow And Earnings

Insight Enterprises (NSIT) Could Be 39% Above Fair Value Following Earnings Update

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Why Insight Enterprises Stock Is Back In Focus Insight Enterprises (NSIT) is back on investor watch after reporting second quarter 2026 earnings and impairment charges on a …

Ensign Energy Services Q2 Earnings Call Highlights

IMDX Looks 289.5% Overvalued on GF Value™

Insight Molecular Diagnostics Inc (IMDX) is considered 284.7% overvalued based on its GF Value™ despite optimism around future FDA authorization for its GraftAssureDx test and expanded Medicare reimbursement. The company reported a Q2 adjusted EBITDA loss and an upward revision of its cash burn …

Insight Molecular Diagnostics Q2 2026 Earnings Preview

* Insight Molecular Diagnostics Inc. (IMDX [https://seekingalpha.com/symbol/IMDX]) is scheduled to announce Q2 earnings results on Monday, August 10th, after market close. * The consensus EPS estimate is -$0.25, [https://seekingalpha.com/symbol/IMDX/earnings/estimates] and the consensus revenue estimate is $0.44M * Over the last year, IMDX has beaten …

Nano Dimension(NNDM) Stock Options Chain | Quotes & News

This article provides access to the stock options chain for Nano Dimension (NNDM), including quotes and news. It serves as a resource for investors interested in NNDM's options trading data.

California State Teachers Retirement System Has $3.78 Million Stake in Sensient Technologies Corporation $SXT

The California State Teachers Retirement System increased its stake in Sensient Technologies Corporation (NYSE:SXT) by 26.4% in the first quarter, now holding 43,777 shares valued at $3.78 million. Sensient Technologies exceeded Q1 earnings and revenue expectations, with adjusted EPS of $1.20 and revenue of …

AdvanSix (ASIX) Stock Sinks As Margin Pressure Clouds Profit Recovery

AdvanSix (ASIX) stock fell 18% after its Q2 2026 earnings report, despite flipping back to a profit of US$0.12 EPS on US$421.3m revenue. The market reacted to significant margin pressure, with net income and adjusted EBITDA sharply down year-over-year, indicating fragile earnings. While pricing …

Sensient Technologies Corp (SXT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Insight Enterprises, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

This article analyzes Insight Enterprises, Inc.'s recent financial performance, highlighting that the company surpassed analyst estimates for its latest quarter. It also provides a forward-looking perspective by detailing what analysts are forecasting for the company's performance in the upcoming year. The content will likely …

Insight Enterprises (NSIT) Stock Flat As AI Margins Reset The Debate

Insight Enterprises (NSIT) stock remained flat despite reporting strong Q2 2026 earnings, including a 65% increase in net income and a 29% rise in adjusted EBITDA, driven by high-margin AI and cloud work. The market's muted reaction suggests investors are still evaluating whether the …

Renaissance Technologies LLC Sells 53,100 Shares of Sensient Technologies Corporation $SXT

Renaissance Technologies LLC reduced its stake in Sensient Technologies Corporation (NYSE:SXT) by 54.6% in the first quarter, selling 53,100 shares but still retaining 44,100 shares valued at approximately $3.8 million. Despite this sale, institutional investors collectively own a significant 90.86% of SXT. Sensient Technologies …

AdvanSix stock drops over 20% amid sharp profit fall and weak market demand, with recovery expected in 5-6 quarters.

AdvanSix: Challenges Persist, My Downgrade Was Correct (NYSE:ASIX)

Ensign Energy Services (TSX:ESI) Stock Price Tracks Revenue Growth Against Debt Doubts

Insight Enterprises Inc (NSIT) (Q2 2026) Earnings Call Highlights: EPS Soars 44% as Cloud and ...

Insight Enterprises Inc. (NSIT) reported strong Q2 2026 earnings, with adjusted diluted EPS soaring 44% and net revenue increasing by 15%. This growth was primarily driven by a 39% increase in cloud gross profit and a 21% rise in hardware revenue, especially in AI-ready …

PensionBee Group PLC Actuals & Estimates (LSE:PBEE)